RxDoctor Payments Data

John French, MD

Ophthalmology · Southern Pines, NCNPI 1366649345

Payments from drug & device makers

$9,412in general payments, 2019–2025

Across 144 payments — averaging $65.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$4K
  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Alcon$1K
  • Biotissue Holdings Inc.$572
  • Glaukos Corporation$347
  • Dompe US, Inc.$265
  • plus $751 from 15 others

What the payments were for

  • Consulting fees$2,13239%
  • Food & beverage$3,31561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,412 in reported general payments places this provider in the 80th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$576,264
Medicare patients
753
Services billed
2,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate950$36,286
RestasisCyclosporine30$30,727
JardianceEmpagliflozin14$8,106
Fluorometholone60$5,931
Loteprednol Etabonate23$5,056
Ofloxacin425$4,609
ValacyclovirValacyclovir Hcl86$4,353
MoxifloxacinMoxifloxacin Hcl63$1,436
Latanoprost56$584
Timolol Maleate18$410
Ketorolac Tromethamine19$387
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim42$320
Dorzolamide Hcl13$262
Brimonidine Tartrate30$240
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$42$30,72730 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$23$5,05623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Southern Pines

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →